英伟达与罗氏制药旗下的Genentech近日宣布合作开发AI平台，旨在加速药物发现和开发。双方将在NVIDIA DGX Cloud上构建AI模型，并利用Genentech的BioNeMo平台让生物技术公司能够大规模定制模型。此外，BioNeMo云应用程序编程接口将被直接集成到计算药物发现工作流程中。
此次合作利用了英伟达在AI领域的领先地位和罗氏制药在药物研发领域的专业经验，旨在为全球患者提供更高效、更安全的治疗方法。通过共同使用AI平台，英伟达和罗氏制药可以更好地了解药物研发过程，并预测药物反应。这将有助于缩短药物研发时间，降低成本，同时提高药物的疗效和安全性。
英伟达与罗氏制药的合作不仅有助于加速药物研发进程，还将促进全球健康事业的共同发展。双方将继续在AI药物研发领域进行深入研究，并探索更多应用场景，为人类健康事业做出更大的贡献。
英文标题：NVIDIA, Genentech Collaborate to Develop AI Platform for Drug Discovery and Development
英文翻译：NVIDIA and Genentech, in partnership, are developing an AI platform to accelerate drug discovery and development. The platform will be built on the NVIDIA DGX Cloud and will utilize Genentech’s BioNeMo platform to enable biotechnology companies to mass-produce custom models. Furthermore, the BioNeMo cloud application programming interface will be directly integrated into the drug discovery workflow. This collaboration leverages NVIDIA’s expertise in the AI field and Genentech’s experience in drug discovery to provide more efficient and safer treatments for patients worldwide. By working together, NVIDIA and Genentech can better understand the drug discovery process, predict drug reactions, and ultimately shorten the development time, reduce costs, and enhance the efficacy and safety of drugs. This collaboration not only helps accelerate the drug discovery process but also promotes the common development of the global health sector. Both parties will continue to study and explore more application scenarios in the AI drug discovery field and work together to make greater contributions to human health.
【来源】https://www.chinastarmarket.cn/detail/1524187
Views: 1